Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 4NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Classical hematology 1

Conditions

Multiple Myeloma 8Prostatic Neoplasms 6Neoplasms, Plasma Cell 6Sarcoma 5Neoplasms 5Melanoma 4Liver Neoplasms 4Leukemia, Lymphocytic, Chronic, B-Cell 4Carcinoma, Hepatocellular 4Lymphoma, Follicular 3Leukemia 3Carcinoma, Renal Cell 3Brain Neoplasms 3Myelodysplastic Syndromes 2Lymphoma 2Kidney Neoplasms 2HIV Infections 2Endometrial Neoplasms 2Carcinoma, Ovarian Epithelial 2Acquired Immunodeficiency Syndrome 2Waldenstrom Macroglobulinemia 1Urologic Neoplasms 1Unspecified Adult Solid Tumor, Protocol Specific 1Stomatitis, Aphthous 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma, Endometrial Stromal 1Recurrent Uterine Corpus Sarcoma 1Rectal Neoplasms 1Ovarian Neoplasms 1Osteosarcoma 1

Interventions

Cytarabine 11fludarabine phosphate 8Peripheral Blood Stem Cell Transplantation 7Etoposide 7Filgrastim 6Daunorubicin 6Vorinostat 5Specimen Handling 5Decitabine 5Cyclophosphamide 5Busulfan 5Biopsy 5Methotrexate 4Cyclosporine 4venetoclax 3sargramostim 3decitabine and cedazuridine drug combination 3Liposomes 3Injections 3Idarubicin 3CPX-351 3Azacitidine 3tipifarnib 2romidepsin 2pomalidomide 2laromustine 2fludarabine 2Vincristine 2Tretinoin 2Transplantation 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Myeloproliferative Disorders × Thalidomide × Clear all
NCT00053001 2013-06-26

Thalidomide and Epoetin Alfa in Treating Anemia in Patients With Myelodysplastic Syndrome

National Cancer Institute (NCI)

Phase 2 Completed
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorders, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative

Data powered by HemOnc (CC BY 4.0) Colophon âš¡